{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:53:32Z","timestamp":1791406412731,"version":"4.3.3"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xphs.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:44:14Z","timestamp":1734363854000},"page":"1164-1174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2901-1355","authenticated-orcid":false,"given":"Jabia M.","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2553-5647","authenticated-orcid":false,"given":"Eduardo A.","family":"Chacin Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7009-2664","authenticated-orcid":false,"given":"Matthew P.","family":"Ohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-0263","authenticated-orcid":false,"given":"Katelyn E.","family":"Swindle-Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-5703","authenticated-orcid":false,"given":"Ashlee N.","family":"Ford Versypt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2024.12.005_bib0001","doi-asserted-by":"crossref","first-page":"E144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: the right to sight: an analysis for the global burden of disease study","volume":"9","author":"Steinmetz","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xphs.2024.12.005_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vis"},{"issue":"R1","key":"10.1016\/j.xphs.2024.12.005_bib0003","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/hmg\/ddx228","article-title":"Genetics of age-related macular degeneration (AMD)","volume":"26","author":"DeAngelis","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.xphs.2024.12.005_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archophthalmol.2009.58","article-title":"Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments","volume":"127","author":"Rein","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"29\u201330","key":"10.1016\/j.xphs.2024.12.005_bib0005","first-page":"513","article-title":"The diagnosis and treatment of age-related macular degeneration","volume":"117","author":"Stahl","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.xphs.2024.12.005_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.612812","article-title":"Age-related macular degeneration revisited: from pathology and cellular stress to potential therapies","volume":"8","author":"Hadziahmetovic","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.xphs.2024.12.005_bib0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.18240\/ijo.2022.01.23","article-title":"Progress of clinical therapies for dry age-related macular degeneration","volume":"15","author":"Rubner","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.xphs.2024.12.005_bib0008","series-title":"2019 Scientific Meeting on Electrical-Electronics & Biomedical Engineering and Computer Science (EBBT)","first-page":"1","article-title":"Dry and wet age-related macular degeneration classification using OCT images and deep learning","author":"Serener","year":"2019"},{"key":"10.1016\/j.xphs.2024.12.005_bib0009","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jconrel.2023.09.021","article-title":"Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration","volume":"363","author":"Chacin Ruiz","year":"2023","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2024.12.005_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fernandez","year":"2020","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.xphs.2024.12.005_bib0011","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.xphs.2024.12.005_bib0012","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"10.1016\/j.xphs.2024.12.005_bib0013","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.xphs.2024.12.005_bib0014","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/jop.2013.0009","article-title":"Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes","volume":"29","author":"Ahn","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2024.12.005_bib0015","first-page":"653","article-title":"Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits","volume":"8","author":"Ye","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"8","key":"10.1016\/j.xphs.2024.12.005_bib0016","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.iae.0000233327.68433.02","article-title":"Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients","volume":"26","author":"Beer","year":"2006","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.xphs.2024.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.xphs.2024.12.005_bib0018","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1076\/ceyr.16.7.663.5061","article-title":"Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume","volume":"16","author":"Friedrich","year":"1997","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.xphs.2024.12.005_bib0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF02648045","article-title":"Finite element modeling of drug distribution in the vitreous humor of the rabbit eye","volume":"25","author":"Friedrich","year":"1997","journal-title":"Ann Biomed Eng"},{"issue":"3","key":"10.1016\/j.xphs.2024.12.005_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2005.03.010","article-title":"Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant","volume":"105","author":"Park","year":"2005","journal-title":"J Control Release"},{"issue":"8","key":"10.1016\/j.xphs.2024.12.005_bib0021","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s11095-010-0163-1","article-title":"Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model","volume":"27","author":"Missel","year":"2010","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2024.12.005_bib0022","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11095-010-0356-7","article-title":"Contribution of saccadic motion to intravitreal drug transport: theoretical analysis","volume":"28","author":"Balachandran","year":"2011","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2024.12.005_bib0023","first-page":"194","article-title":"Computer modeling of drug distribution after intravitreal administration","volume":"5","author":"Haghjou","year":"2011","journal-title":"Int J Pharmacol Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2024.12.005_bib0024","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","article-title":"Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes","volume":"29","author":"Missel","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2024.12.005_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mbs.2014.06.008","article-title":"Computational modeling of drug distribution in the posterior segment of the eye: effects of device variables and positions","volume":"255","author":"Jooybar","year":"2014","journal-title":"Math Biosci"},{"key":"10.1016\/j.xphs.2024.12.005_bib0026","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1023\/A:1022207026982","article-title":"Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor","volume":"20","author":"Stay","year":"2003","journal-title":"Pharm Res"},{"issue":"23\u201324","key":"10.1016\/j.xphs.2024.12.005_bib0027","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.ijheatmasstransfer.2008.04.053","article-title":"Computational modeling of intravitreal drug delivery in the vitreous chamber with different vitreous substitutes","volume":"51","author":"Kathawate","year":"2008","journal-title":"Int J Heat Mass Transfer"},{"issue":"9","key":"10.1016\/j.xphs.2024.12.005_bib0028","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol Pharmaceutics"},{"issue":"7","key":"10.1016\/j.xphs.2024.12.005_bib0029","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1021\/acs.molpharmaceut.8b00280","article-title":"Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic\/pharmacodynamic model","volume":"15","author":"Hutton-Smith","year":"2018","journal-title":"Mol Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2024.12.005_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1124\/jpet.119.263178","article-title":"A mechanistic and translational pharmacokinetic-pharmacodynamic model of abicipar pegol and vascular endothelial growth factor inhibition","volume":"373","author":"Luu","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2024.12.005_bib0031","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.12.005_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/pharmaceutics11010009","article-title":"Pharmacokinetic simulations of intravitreal biologicals: aspects of drug delivery to the posterior and anterior segments","volume":"11","author":"Rimpela","year":"2019","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2024.12.005_bib0033","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0006-3495(80)85152-6","article-title":"In vivo measurements of the viscoelasticity of the human vitreous humor","volume":"29","author":"Zimmerman","year":"1980","journal-title":"Biophys J"},{"issue":"2","key":"10.1016\/j.xphs.2024.12.005_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jop.2012.0138","article-title":"The vitreous humor as a barrier to nanoparticle distribution","volume":"29","author":"Mains","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xphs.2024.12.005_bib0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fbioe.2018.00199","article-title":"Rheological properties and age-related changes of the human vitreous humor","volume":"6","author":"Tram","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"issue":"113","key":"10.1016\/j.xphs.2024.12.005_bib0036","doi-asserted-by":"crossref","DOI":"10.3791\/53878","article-title":"Use of rabbit eyes in pharmacokinetic studies of intraocular drugs","author":"Ahn","year":"2016","journal-title":"J Visualized Exp"},{"issue":"1","key":"10.1016\/j.xphs.2024.12.005_bib0037","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.9.1.2","article-title":"In vivo measurement of the human vitreous chamber volume using computed tomography imaging of 100 eyes","volume":"9","author":"Azhdam","year":"2020","journal-title":"Transl Vision Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2024.12.005_bib0038","doi-asserted-by":"crossref","first-page":"031208","DOI":"10.1115\/1.4053197","article-title":"Mathematical model of macromolecular drug transport in a partially liquefied vitreous humor","volume":"144","author":"Khoobyar","year":"2022","journal-title":"J Heat Transfer"},{"issue":"12","key":"10.1016\/j.xphs.2024.12.005_bib0039","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2013a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.xphs.2024.12.005_bib0040","doi-asserted-by":"crossref","first-page":"032101","DOI":"10.1115\/1.4049033","article-title":"In vivo experimental and analytical studies for bevacizumab diffusion coefficient measurement in the rabbit vitreous humor","volume":"143","author":"Zhang","year":"2021","journal-title":"J Heat Transf"},{"key":"10.1016\/j.xphs.2024.12.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109162","article-title":"Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-vegf macromolecules using published human and rabbit data","volume":"222","author":"Lamminsalo","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xphs.2024.12.005_bib0042","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00397-017-0997-0","article-title":"Rheological behaviour of vitreous humour","volume":"56","author":"Silva","year":"2017","journal-title":"Rheol Acta"},{"issue":"8","key":"10.1016\/j.xphs.2024.12.005_bib0043","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11095-018-2435-0","article-title":"Extended pharmacokinetic model of the rabbit eye for intravitreal and intracameral injections of macromolecules: quantitative analysis of anterior and posterior elimination pathways","volume":"35","author":"Lamminsalo","year":"2018","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2024.12.005_bib0044","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s11095-008-9691-3","article-title":"Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow","volume":"25","author":"Balachandran","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2024.12.005_bib0045","series-title":"Clinical Anatomy of the Visual System","author":"Remington","year":"2011"},{"key":"10.1016\/j.xphs.2024.12.005_bib0046","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2147\/OPTH.S95956","article-title":"Macular thickness and macular volume measurements using spectral domain optical coherence tomography in normal nepalese eyes","volume":"10","author":"Pokharel","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xphs.2024.12.005_bib0047","first-page":"45","article-title":"How to give intravitreal injections","author":"Wilson","year":"2013","journal-title":"EyeNet Ophthalmic Pearls"},{"issue":"2","key":"10.1016\/j.xphs.2024.12.005_bib0048","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1615\/JPorMedia.2020028229","article-title":"Measurement of the hydraulic conductivity of the vitreous humor","volume":"23","author":"Penkova","year":"2020","journal-title":"J Porous Media"},{"key":"10.1016\/j.xphs.2024.12.005_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.matlet.2021.131080","article-title":"In silico model of bevacizumab sustained release from intravitreal administrated PLGA drug-loaded microspheres","volume":"307","author":"Heljak","year":"2022","journal-title":"Mater Lett"},{"key":"10.1016\/j.xphs.2024.12.005_bib0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2023.11.015","article-title":"Investigating bevacizumab and its fragments sustained release from intravitreal administrated PLGA microspheres: a modeling approach","volume":"193","author":"Heljak","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.xphs.2024.12.005_bib0051","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/iovs.65.4.9","article-title":"Drug distribution after intravitreal injection: a mathematical model","volume":"65","author":"Ruffini","year":"2024","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"10","key":"10.1016\/j.xphs.2024.12.005_bib0052","doi-asserted-by":"crossref","DOI":"10.1115\/1.4051785","article-title":"Analytical and computational modeling of sustained-release drug implants in the vitreous humor","volume":"143","author":"Khoobyar","year":"2021","journal-title":"J Heat Transf"},{"key":"10.1016\/j.xphs.2024.12.005_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100845","article-title":"No flow through the vitreous humor: how strong is the evidence?","volume":"78","author":"Smith","year":"2020","journal-title":"Prog Retinal Eye Res"},{"key":"10.1016\/j.xphs.2024.12.005_bib0054","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.xphs.2024.12.005_bib0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/scipharm90010005","article-title":"A new practice to monitor the fabrication process of fab-targeting ligands from bevacizumab by lc-ms: preparation and analytical characterization","volume":"90","author":"Marquet","year":"2022","journal-title":"Sci Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.12.005_bib0056","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1590\/S1516-89132011000100010","article-title":"In vivo investigation of radiolabeled bevacizumab in healthy rat tissues","volume":"54","author":"Demir","year":"2011","journal-title":"Braz Arch Biol Technol"},{"key":"10.1016\/j.xphs.2024.12.005_bib0057","unstructured":"COMSOL Multiphysics\u00aev. 6.1. Stockholm, Sweden: COMSOL AB; https:\/\/www.comsol.com."},{"issue":"4","key":"10.1016\/j.xphs.2024.12.005_bib0058","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mam.2012.06.003","article-title":"Animal models of age related macular degeneration","volume":"33","author":"Pennesi","year":"2012","journal-title":"Mol Aspects Med"},{"issue":"2","key":"10.1016\/j.xphs.2024.12.005_bib0059","first-page":"131","article-title":"Morphologic and physiologic retinal degeneration induced by intravenous delivery of vitamin a dimers in the leporid retina","volume":"8","author":"Penn","year":"2014","journal-title":"Dis Models Mech"},{"issue":"10","key":"10.1016\/j.xphs.2024.12.005_bib0060","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.xphs.2024.12.005_bib0061","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-vegf antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.xphs.2024.12.005_bib0062","unstructured":"Rohatgi A.. WebPlotDigitizer, Version 4.6; 2023; Accessed May 8 https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"10.1016\/j.xphs.2024.12.005_bib0063","unstructured":"Chowdhury J.M., Chacin Ruiz E.A., Ford Versypt A.N.. PBPKHumanRabbitEyes;. Accessed July 6, 2024;https:\/\/github.com\/ashleefv\/PBPKHumanRabbitEyes. 10.5281\/zenodo.12667703"},{"issue":"8","key":"10.1016\/j.xphs.2024.12.005_bib0064","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garcia-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.12.005_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpharm.2019.118767","article-title":"Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration","volume":"573","author":"Luaces-Rodriguez","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.12.005_bib0066","first-page":"1","article-title":"Effect of fluid flow direction on intravitreal injections of drugs into eye","author":"Sibak","year":"2023","journal-title":"Heat Transfer Eng"},{"issue":"3","key":"10.1016\/j.xphs.2024.12.005_bib0067","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11242-023-02052-x","article-title":"Flow characterization in a partially liquefied vitreous humor","volume":"151","author":"Khoobyar","year":"2024","journal-title":"Transp Porous Media"},{"issue":"8","key":"10.1016\/j.xphs.2024.12.005_bib0068","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.drudis.2019.05.039","article-title":"Physiologically based ocular pharmacokinetic modeling using computational methods","volume":"24","author":"Missel","year":"2019","journal-title":"Drug Discovery Today"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924006075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924006075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T18:21:20Z","timestamp":1742667680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924006075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0022354924006075"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.12.005","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.05.05.539491","asserted-by":"object"}]},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}